Current Complaints | Help Center| Subscribe

Recent:

Data for the month ending - Aug, 2026

Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

^ Average Resolution time is the sum total of time taken to resolve each complaint in days, in the current month divided by total number of complaints resolved in the current month.

Trend of Monthly Disposal of Complaints

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

Trend of Annual Disposal of Complaints

Sr. No.	Fin. Year	Received	Resolved*
1	2021-22	1	1
2	2022-23	1	1
3	2023-24	0	0
4	2024-25	0	0
	Grand Total	2	2

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Vista Pharmaceuticals awaits for USFDA approval for launch of generic Dofetilide

Vista Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524711 | NSE:

04 Jan 2019 Evaluate

Vista Pharmaceuticals has completed all data filings and up to date in GDUFA fee payments for 2019 and is waiting for approval from USFDA for commercial launch of generic Dofetilide.

Vista Pharmaceuticals had filed an ANDA in September 2017 Dofetilide (Brand: TIKOSYN) in financial partnership with Biddle Sawyer, USA.

TIKOSYN (Generic: Dofetilide) is a CARDIAC drug which went OFF PATENT on October 09, 2018 and the drug molecule, TIKOSYN is owned by Pfizer.

Upon approval of Dofetilide ANDA, the company will join the exclusive club of other 4 Generic Manufacturers (Sun, Greenstone, Bion, Mayne/Sigma). The size of the market is over $ 200 million (Rs 1,400 crore approximately).

Vista Pharmaceuticals is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations. The company also sells the products to its related companies, which are engaged in the manufacture of formulations.

Peers

Company Name	CMP
Sun Pharma. Inds.	1820.00
Dr. Reddys Labs.	1236.00
Cipla	1350.00
Lupin	2042.00
Zydus Lifesciences	1163.35
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.